NeuroDerm Parkinson's Drug Eligible For EU Centralized Procedure
NeuroDerm, a clinical stage pharmaceutical company focused on central nervous system (CNS) products, announced that the European Medicines Agency (EMA) pronounced eligibility of its Parkinson’s drug ND0612H for the European Union Centralized Procedure. ND0612H is a high dose form of liquid levodopa/carbidopa (LD/CD) administered subcutaneously and continuously by a belt pump. The drug is intended to reduce the motor challenges that occur in the advanced stages of Parkinson’s disease through regular administration of high therapeutic levodopa plasma levels. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - August 5, 2014 Category: Pharmaceuticals Source Type: news
Compound Formula Rehmannia alleviates dyskinesia in Parkinson's disease
(Neural Regeneration Research) Levodopa is the preferred treatment for Parkinson's disease in the clinic. However, long-term use of levodopa may lead to various motor complications, among which levodopa-induced dyskinesia is the most common, severely affecting patients' quality of life. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2014 Category: Global & Universal Source Type: news
Best Initial Therapy for Parkinson DiseaseBest Initial Therapy for Parkinson Disease
The benefits of levodopa vs levodopa-sparing therapies are tested in this large, open-label trial. Medscape Neurology (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - July 24, 2014 Category: Neurology Tags: Neurology & Neurosurgery Commentary Source Type: news
Levodopa Shows Slight Edge As Initial Treatment for Parkinson's
Source: Parkinson's Disease Foundation
Related MedlinePlus Page: Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 26, 2014 Category: Consumer Health News Source Type: news
Levodopa Best Choice for Initial Parkinson's TreatmentLevodopa Best Choice for Initial Parkinson's Treatment
The largest ever drug trial in Parkinson's disease found that levodopa beats dopamine agonists and monoamine oxidase type B inhibitors in terms of patient-reported mobility, quality of life, and other measures. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 11, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Levodopa May Beat Newer Meds for Long-Term Parkinson's Care
Largest such trial finds the older drug 'edging out' others, but treatment is made on case-by-case basisSource: HealthDay
Related MedlinePlus Page: Parkinson's Disease (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 11, 2014 Category: Consumer Health News Source Type: news
Trial in Parkinson's disease shows that for long-term treatment levodopa is better than newer drugs
An NIHR Health Technology Assessment (HTA) Programme-funded study has published its findings in The Lancet. For long-term treatment of newly diagnosed Parkinson’s disease (PD), the old drug levodopa provides better mobility and a higher quality of life than the two main alternatives, dopamine agonists (DA) and monoamine oxidase type B inhibitors (MAOBI), according to... (Source: NIHR Evaluation, Trials and Studies News)
Source: NIHR Evaluation, Trials and Studies News - June 11, 2014 Category: American Health Source Type: news
Reliable L-Dopa Tops for Early Parkinson's (CME/CE)
(MedPage Today) -- A large clinical trial gave a small edge to levodopa over dopamine agonists and monoamine oxidase B inhibitors as initial therapy in Parkinson's disease, researchers said. (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - June 10, 2014 Category: Neurology Source Type: news
Adamas starts Phase III trial of ADS-5102 to treat PD patients with levodopa-induced dyskinesia
US-based Adamas Pharmaceuticals has started a pivotal Phase III clinical trial of its most advanced wholly owned product candidate ADS-5102 (amantadine HCl) for the treatment of patients with Parkinson's disease (PD) who have developed movement disor… (Source: Drug Development Technology)
Source: Drug Development Technology - June 10, 2014 Category: Pharmaceuticals Source Type: news
Newron submits new drug application to FDA for Parkinson's disease treatment
Newron Pharmaceuticals has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for safinamide, which is being developed as an add-on therapy to dopamine agonists or to levodopa in patients with early or mid-to-late-sta… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 29, 2014 Category: Pharmaceuticals Source Type: news
Civitas reports positive Phase IIb trial results of Parkinson's disease treatment
Civitas Therapeutics has released positive results from a Phase IIb clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa), being developed for the treatment of intermittent debilitating motor fluctuations (OFF episodes) associated wi… (Source: Drug Development Technology)
Source: Drug Development Technology - April 28, 2014 Category: Pharmaceuticals Source Type: news
Lodosyn (Carbidopa) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 10, 2014 Category: Drugs & Pharmacology Source Type: news
Proceedings of the National Academy of Sciences USA online: March 5, 2014
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia Myriam Heiman, Adrian Heilbut,Veronica Francardo, Ruth Kulicke, Robert J. Fenster, Eric D. Kolaczyk, Jill P. Mesirov, Dalton J. … More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - March 5, 2014 Category: Biomedical Science Authors: pubaff Tags: Research Update Source Type: news
Hot Topics: Advances in Parkinson's
(MedPage Today) -- What works and what doesn't work in Parkinson's? We asked four experts in the field for their take. Their answers encompassed surgical interventions, levodopa as the "gold standard," managing disease, and the role of exercise. (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 19, 2014 Category: Primary Care Source Type: news
Amantadine Has Lasting Benefit on Levodopa-Induced DyskinesiaAmantadine Has Lasting Benefit on Levodopa-Induced Dyskinesia
A large study shows a 'clinically important' and long-lasting antidyskinetic effect of amantadine in Parkinson's patients receiving levodopa. Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - January 8, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
